A study of the relationship between plasma concentrations of linezolid and its relationship with the frequency of adverse events and discontinuation factors.

A study of the relationship between plasma concentrations of linezolid and its relationship with the frequency of adverse events and discontinuation factors. - A study of the relationship between plasma concentrations of linezolid and its relationship with the frequency of adverse events and discontinuation factors.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054268

Enrollment

Registered

2024-06-01

Start date

2024-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infectious disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients 18 years of age or older who received linezolid. Patients diagnosed with an infectious disease requiring linezolid between June 1, 2024 and December 31, 2026. Patients who give written consent to participate in this study.

Exclusion criteria

Exclusion criteria: Patients allergic to LZD Patients with disseminated intravascular coagulation syndrome

Design outcomes

Primary

Measure	Time frame
Evaluate the association between plasma concentrations of LZD and incidence of thrombocytopenia and history of dose interruptions and dose interruption factors.	—

Secondary

Measure	Time frame
Differences between the present study in city hospitals and previous reports, mainly in university hospitals, are discussed.	—

Countries

Japan

Contacts

Public ContactDaiki Yamaguchi

Gifu Prefectural Tajimi Hospital pharmaceutical department

yamaguchi-daiki@tajimi-hospital.jp0572-22-5311

Outcome results